Skip to content

The effect of telmisartan on the pharmacokinetics and pharmacodynamics of metformin

The effect of telmisartan on the pharmacokinetics and pharmacodynamics of metformin

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-IPR-14005491
Enrollment
Unknown
Registered
2014-11-15
Start date
2014-11-15
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertension

Interventions

telmisartan group :telmisartan

Sponsors

Institute of Clinical Pharmacology, Xiangya Hospitol, Central South University
Lead Sponsor

Eligibility

Sex/Gender
Male
Age
18 Years to 45 Years

Inclusion criteria

Inclusion criteria: (1) Healthy subjects; (2) Age 18-45 years, males

Exclusion criteria

Exclusion criteria: (1) History of drug abuse; (2) Consuming more than two alcoholic drinks twice a week; (3)Smoking more than ten cigarettes a day.

Design outcomes

Primary

MeasureTime frame
plasma concentration of metformin;plasma glucose and insulin;

Countries

China

Contacts

Public ContactZhang Wei
yjsd2003@163.com+86 0731 84805380

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026